MedTrace Logo

Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia

NCT00809679 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2012-06-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of T-62 in subjects with postherpetic neuralgia.

Conditions

  • Postherpetic Neuralgia

Interventions

DRUG

T-62 Dose 1

Capsule dosage form 100 mg bid

DRUG

T-62 Dose 2

Capsule dosage form 200 mg bid

OTHER

Placebo

Capsule dosage form placebo bid

Sponsors & Collaborators

Principal Investigators

  • Robert L. Rolleri, Pharm. D. · King Pharmaceuticals is now a wholly owned subsidiary of Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00809679 on ClinicalTrials.gov